RecruitingNot Applicable

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

United States200 participantsStarted 2025-07-17

Plain-language summary

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adverse pathologic features at the time of prostatectomy (positive surgical margin, pathologic T-stage 3-4 disease, pathologic Gleason score 8-10 disease, OR presence of tertiary Gleason grade 5 disease)
✓. Documentation of rising prostate-specific antigen on at least two consecutive draws, with the magnitude of prostate-specific antigen exceeding 0.03 ng/mL
✓. Intermediate- or high-risk Decipher genomic classifier score
✓. Identification of prostate cancer in ≥1 lymph node at the time of prostatectomy (pN+ disease)

What they're measuring

Genitourinary Domain Score

Timeframe: 5 years

Trial details

NCT IDNCT07077239

SponsorJonsson Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2035-08-01

Contact for this trial

CHRISTY PALODICHUK

+1 310-794-2971 cpalodichuk@mednet.ucla.edu

View on ClinicalTrials.gov More Prostate Cancer (CRPC) trials